Long bone fractures heal faster after injections of bone-building cells. Research published in the open access journal BMC Musculoskeletal Disorders has shown that osteoblast cells cultured from a patient's own bone marrow can be injected into the fracture area and can speed the healing process.
Dr Seok-Jung Kim from the Catholic University College of Medicine, Seoul, coordinated a multi-centre, randomized clinical study of the osteoblast treatment. He said, "The cultured osteoblast injection group showed fracture healing acceleration of statistical significance, and there were no specific patient complications when using this treatment. Cultured osteoblast injection should therefore be considered as a successful treatment option for long-bone fracture".
Between May 2006 and January 2008, 64 patients were included in the study. Of these, 31 were randomly allocated to receive the treatment and 33 were left to heal normally as a control group. There were no significant age, sex or body-shape differences between the two groups. According to Dr Kim, "There was significantly more bone growth in the experimental group, compared to the control group. Autologous cultured osteoblast transplant is a safe and effective method for accelerating the rate of fracture healing."
Dr Kim added, "Time has increasingly become the most important factor in clinical decision-making. While fractures generally will eventually heal, bone union can frequently be delayed to the extent that it requires bone transplantation. Not only does this cause psychological and physical pain to the individual patient, it's also not economically viable. Although bone transplant remains the most effective method of bone union, osteoblast injections provide an alternative which can be performed under local anesthesia with no requirement for surgery".
Notes to Editors
1. A multi-center, randomized, clinical study to compare the effect and safety of autologous cultured osteoblast(OssronTM) injection to treat fractures
Seok-Jung Kim, Yong-Woon Shin, Kyu-Hyun Yang, Sang-Bum Kim, Moon-Jib Yoo, Suk-Ku Han, Soo-Ah Im, Yoo-Dong Won, Yerl-Bo Sung, Taek-Soo Jeon, Cheong-Ho Chang, Jae-Deog Jang, Sae-Bom Lee, Hyun-Jo Kim and Su-Young Lee
BMC Musculoskeletal Disorders (in press)
During embargo, article available here: http://www.biomedcentral.com/imedia/5723081821952584_article.pdf?random=571089
After the embargo, article available at journal website: http://www.biomedcentral.com/bmcmusculoskeletdisord/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication
2. BMC Musculoskeletal Disorders is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of musculoskeletal and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology. BMC Musculoskeletal Disorders (ISSN 1471-2474) is indexed/tracked/covered by PubMed, MEDLINE, CAS, Scopus, EMBASE, Current Contents, Thomson Reuters (ISI) and Google Scholar.
3. BioMed Central (www.biomedcentral.com) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.